PPT-Non-diabetes Outcomes Cardiovascular

Cyrus Desouza MD October 22 2017 Why 1A Evaluate the effect of vitamin D supplementation on incident CVD in people with prediabetes 1B Establish CVD risk in people with prediabetes defined by the modern ADA criteria. Applying evidence based medicine to clinical care. Cardiovascular disease is the biggest killer in UK. Number. of . deaths. (000’s). 124,037. 60,666. 18,165. 33,634. 16,216. 12,762. 103,431. 19,996. FDA-Mandated CV Safety Trials. 1. TECOS. (Trial Evaluating Cardiovascular Outcomes with Sitagliptin). Clinical Outcomes with Antihyperglycemic Agents. 2. Clinical Outcomes with Sitagliptin. Study Design. Deepak L. Bhatt, MD, MPH. Professor . of Medicine, Harvard Medical School. Executive Director of Interventional Cardiovascular Programs. Brigham & Women’s Hospital Heart and Vascular Center. Boston, Massachusetts. 1. Obesity. Management of Common Comorbidities in Diabetes. 2. 3. 4. More Than Two Thirds of US Adults Are Overweight or Obese. 5. *2014 rate of overweight not reported in . Flegal. et al 2016; 2012 rate carried over based on historic stability of overweight prevalence.. CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. Antidiabetes. Medications:. Cardiovascular Benefits. Hengameh. . Abdi. Endocrine Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 13 December 2018. European Association for the Study of Diabetes. Lisbon, . 13. th. . September 2017. ISRCTN number: 91899513. ClinicalTrials.gov number: . NCT00829660. Study Rationale, Design and Conduct. The Diabetes Burden. David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . TECOS Executive Committee MemberRury R. Holman, MB, ChBDiabetes Trials Unit, OCDEM Churchill Hospital, Oxford, United KingdomTECOS CoPrincipal Investigator andJoint Chair of TECOS Executive CommitteeR and . Meglitinides. in CLINICAL DIABETES . F. . . Hadaegh. Jan. . 2017. 1/12/2017. AGENDA. 3. 1/12/2017. Available treatment algorithms for T. 2. DM. Basic and clinical points. Review on available literatures. Sex . Male. Diabetes. . History. T2D, . onset. @45 . yrs. , treatment: . metformin. , . sitagliptin. and . gliclazide. . Organ. . damage. . evaluation. :. Eyes. : No . signs. of . retinopathy. GGC MCN meeting 5. th. February 2019. John R Petrie. Professor of Diabetic Medicine. University of Glasgow, UK. Advisory and Consultancy Work:. Novo Nordisk, Sanofi-Aventis, Biocon, Astra Zeneca, . Servier. John McMurray. BHF Cardiovascular Research Centre, University of Glasgow . & Queen Elizabeth University Hospital, Glasgow, UK.. On behalf of the DAPA-HF Committees and Investigators. Results in Nondiabetic Patients. Dr Shanti Vijayaraghavan, . Consultant . Diabetologist. , . Barts. Health, London. 15 May 2015. Acute or Short-term Complications. 1. Hypoglycaemia: low blood glucose level. 2. Hyperglycaemia:. Diabetic .